[go: up one dir, main page]

TR200103033T2 - íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon - Google Patents

íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon

Info

Publication number
TR200103033T2
TR200103033T2 TR2001/03033T TR200103033T TR200103033T2 TR 200103033 T2 TR200103033 T2 TR 200103033T2 TR 2001/03033 T TR2001/03033 T TR 2001/03033T TR 200103033 T TR200103033 T TR 200103033T TR 200103033 T2 TR200103033 T2 TR 200103033T2
Authority
TR
Turkey
Prior art keywords
ileum
compound
bile acid
crowning
inhibits
Prior art date
Application number
TR2001/03033T
Other languages
English (en)
Inventor
Abrahamsson Bertil
Lindqvist Ann-Margret
Ungell Anna-Lena
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200103033T2 publication Critical patent/TR200103033T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Oral farmasötik bir formülasyon,ileum safra asidi taç nmas n inhibe eden bir bileçik (IBAT inhibe eden bir bileçik) ve terapötik olarak kabul edilebilir bir taç y c içerir; formülasyonun özelliGi, IBAT inhibitörü olan bileçiGi, ileumda uygulayacak çekilde tasarlanm ç olmas d r. IBAT inhibitörü olan bileçik,bu bileçikle gerçekleçtirilen tedavinin, diyare gibi olas yan etkilerinin hafifletilmesi için bir safra asidi baGlay c madde ile kombinasyon halinde de uygulanabilir. Safra asidi baGlay c , kolonda sal nacak çekilde formüle edilir.
TR2001/03033T 1999-04-19 2000-04-19 íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon TR200103033T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations

Publications (1)

Publication Number Publication Date
TR200103033T2 true TR200103033T2 (tr) 2002-03-21

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03033T TR200103033T2 (tr) 1999-04-19 2000-04-19 íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon

Country Status (26)

Country Link
EP (1) EP1173205B1 (tr)
JP (1) JP2002542208A (tr)
KR (1) KR20010108516A (tr)
CN (1) CN1348384A (tr)
AT (1) ATE296641T1 (tr)
AU (1) AU767425B2 (tr)
BR (1) BR0009835A (tr)
CA (1) CA2379105A1 (tr)
CZ (1) CZ20013743A3 (tr)
DE (1) DE60020551T2 (tr)
DK (1) DK1173205T3 (tr)
EE (1) EE04607B1 (tr)
ES (1) ES2241603T3 (tr)
HU (1) HUP0200793A3 (tr)
IL (1) IL145871A0 (tr)
IS (1) IS2161B (tr)
NO (1) NO20015063L (tr)
NZ (1) NZ514264A (tr)
PL (1) PL351186A1 (tr)
PT (1) PT1173205E (tr)
SE (1) SE9901387D0 (tr)
SI (1) SI1173205T1 (tr)
SK (1) SK15282001A3 (tr)
TR (1) TR200103033T2 (tr)
WO (1) WO2000062810A1 (tr)
ZA (1) ZA200108539B (tr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
CA2403670C (en) * 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Multiparticulate drug form comprising at least two differently coated pellet forms
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
EP1427423B9 (en) 2001-09-08 2017-12-20 AstraZeneca AB Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
DK2531206T3 (en) 2010-02-04 2017-09-11 Morphotek Inc CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
CA2799169C (en) 2010-05-11 2019-07-23 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012064266A1 (en) 2010-11-04 2012-05-18 Albireo Ab Ibat inhibitors for the treatment of liver diseases
ES2586956T3 (es) * 2010-11-08 2016-10-19 Albireo Ab Combinación farmacéutica que comprende un inhibidor de IBAT y un aglutinante de ácidos biliares
CN107375291A (zh) * 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
MX354242B (es) * 2011-10-28 2018-02-20 Lumena Pharmaceuticals Inc Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
RU2015126650A (ru) 2012-12-10 2017-01-12 Фред Хатчинсон Кэнсер Рисёрч Сентер Партнеры липокалина по слиянию
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CA3011619C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017138877A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
AU2017250359B2 (en) 2016-04-15 2022-06-16 Blaze Bioscience, Inc. Methods of treating breast cancer
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
HUE070725T2 (hu) 2018-06-20 2025-06-28 Albireo Ab Odevixibat kristálymódosulatai
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3127568A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3129735A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
WO2021030474A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AU2020397448A1 (en) 2019-12-04 2022-05-26 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
KR20250029896A (ko) 2022-07-05 2025-03-05 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
TW289020B (tr) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
SI1173205T1 (en) 2005-10-31
CA2379105A1 (en) 2000-10-26
ZA200108539B (en) 2003-01-17
EE04607B1 (et) 2006-04-17
CN1348384A (zh) 2002-05-08
DE60020551T2 (de) 2006-03-23
ES2241603T3 (es) 2005-11-01
HUP0200793A3 (en) 2004-07-28
SK15282001A3 (sk) 2002-04-04
PT1173205E (pt) 2005-10-31
DE60020551D1 (de) 2005-07-07
EP1173205A1 (en) 2002-01-23
IS2161B (is) 2006-11-15
JP2002542208A (ja) 2002-12-10
KR20010108516A (ko) 2001-12-07
AU767425B2 (en) 2003-11-13
HK1042850A1 (en) 2002-08-30
AU4633500A (en) 2000-11-02
DK1173205T3 (da) 2005-08-08
SE9901387D0 (sv) 1999-04-19
EP1173205B1 (en) 2005-06-01
NO20015063D0 (no) 2001-10-18
ATE296641T1 (de) 2005-06-15
PL351186A1 (en) 2003-03-24
EE200100545A (et) 2003-02-17
IS6109A (is) 2001-10-16
WO2000062810A1 (en) 2000-10-26
NZ514264A (en) 2003-10-31
IL145871A0 (en) 2002-07-25
CZ20013743A3 (cs) 2002-01-16
NO20015063L (no) 2001-10-18
BR0009835A (pt) 2002-01-08
HUP0200793A2 (hu) 2002-07-29

Similar Documents

Publication Publication Date Title
TR200103033T2 (tr) íleuma uygulanmak zere ileum safra asidinin taçìnmasìnì inhibe eden bir bileçik i‡eren oral bir formlasyon
SE0003766D0 (sv) Novel formulation
SE8302716L (sv) Bicykliska foreningar
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
NO2013002I1 (no) Aklidinium haogenid (Aklidinium bromid)
MY139571A (en) Indolyl derivatives as liver-x-receptor modulators
TR199802102T2 (tr) Antifungal madde ve asetat tampon maddesi içeren bilesimler.
LV11430A (lv) 2-Piridilmetilenpoliazamakrociklofosfonskabes to kompleksi un atvasinajumi izmantosanai par kontrastvielam
EA200401446A1 (ru) Иммуноконъюгаты для лечения опухолей
ATE73771T1 (de) Tricyclische indolderivate, herstellung und anwendung als arzneimittel.
TR199900486T2 (tr) Aziniloksi ve fenoksi-diaril-karbonasit türevleri.
TR199802769T2 (tr) Terpenoid bilesikler ile antihistaminik bilesiklerin bir kombinasyonunu ihtiva eden topikal bilesim.
TR200001140T2 (tr) 6, 11-Köprülü eritromisin türevleri.
MY135646A (en) Indolyl derivatives
ITTO920303A1 (it) Composizione farmaceutica antiinfiammatoria
TR200101337T2 (tr) Değiştirilmiş salımlı ensülin sensitizörü için farmasötik terkip ve kullanımı.
DE69117303D1 (de) Zusammensetzung mit psyllium
IE40661L (en) Tetracyclic piperidino derivatives
NO169487C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,3-dihydrobenzofuran-5-sulfonamider
SE7811455L (sv) 2-imino-imidazolidin-derivat
NO975127L (no) Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater
ATE250610T1 (de) Kaliumkanal-blockierende mittel
TR199901631T2 (tr) Klavülanik asitin esterleri ve tuzlarinin hazirlanmasi için islem.
TR200101444T2 (tr) 8-siyano-1-siklopropil-7- (1S,6S-2,8-diazabisiklo[4.3.0] nonan-8-yl)-6-floro-1, 4-dihidro-4-oxo-3-kunolinkarboksilik asidin kristal B modifikasyonu.